A Small-Molecule CD4-Mimetic Compound Protects Bone Marrow-Liver-Thymus Humanized Mice From HIV-1 Infection.

Abstract

Background:

Small-molecule CD4-mimetic compounds (CD4mc) inhibit human immunodeficiency virus (HIV-1) entry by blocking binding to the CD4 receptor and by premature triggering of the viral envelope glycoprotein (Env) spike.

Methods:

The efficacy of a CD4mc in protecting bone marrow-liver-thymus (BLT) humanized mice from vaginal HIV-1 challenge was evaluated.

Results:

Intravaginal application of the CD4mc JP-III-48, either before or simultaneously with virus challenge, protected BLT humanized mice from HIV-1JR-CSF infection in a dose- dependent manner.

Conclusion:

The direct antiviral effects of a CD4mc prevent HIV-1 infection in a murine model of sexual transmission.

• Authors: Amy M Princiotto, Vladimir D Vrbanac, Bruno Melillo, Jongwoo Park, Andrew M Tager, Amos B Smith 3rd, Joseph Sodroski, Navid Madani
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 218 Issue 3 Pg. 471-475 (07 02 2018) ISSN: 1537-6613 [Electronic] United States
• PMID: 29617845 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• CD4 Antigens
• HIV Fusion Inhibitors

Topics

• Administration, Intravaginal
• Animals
• Biomimetics
• Bone Marrow
• CD4 Antigens (administration & dosage)
• Disease Models, Animal
• Female
• HIV Fusion Inhibitors (administration & dosage)
• HIV Infections (prevention & control)
• HIV-1 (drug effects)
• Liver
• Mice, SCID
• Thymus Gland
• Treatment Outcome